Jobaaj Stories
GlaxoSmithKline Pharmaceuticals (GSK Pharma) shares rallied over 3.2% to close at ₹2,879.70 after the company reported a robust 34.7% year-on-year growth in standalone net profit, reaching ₹260.14 crore for Q4FY25. This surge came on the back of improved operating efficiency and a 6% rise in revenue to ₹966.08 crore.
The company also declared a final dividend of ₹42 per share for FY25, subject to shareholder approval at its upcoming 100th Annual General Meeting.
Key Financial Highlights:
-
Net Profit (Q4FY25): ₹260.14 crore (Up 34.73% YoY)
-
Revenue from Operations: ₹966.08 crore (Up 6.06% YoY)
-
Profit Before Tax: ₹354.90 crore (Up 32.08% YoY)
-
Total Expenses: Fell 3.53% YoY to ₹650.64 crore
-
Material Costs: Down sharply by 43.65%
-
Employee Costs: Declined 11.49% YoY
-
Full-Year Net Profit (FY25): ₹919.06 crore (Up 57.19% YoY)
-
FY25 Revenue: ₹3,723.49 crore (Up 9.28% YoY)
Management Commentary: Strategy & Pipeline
Managing Director Bhushan Akshikar credited the performance to GSK’s diversified portfolio spanning general medicines, specialty drugs, and vaccines. He highlighted strong contributions from brands like Augmentin, Calpol, Ceftum, T-Bact, and Trelegy.
Further, Shingrix, a shingles vaccine, continues to see increasing adoption as GSK deepens its focus on adult immunization in India.
Looking ahead, the company is preparing to launch:
-
Zejula (Niraparib): A PARP inhibitor for ovarian cancer
-
Jemperli (Dostarlimab): An immunotherapy for second-line treatment of endometrial cancer
Jobaaj Insight: Leaner Costs, Strong Pipeline Signal Long-Term Strength
GSK Pharma’s performance this quarter is marked not just by top-line growth, but also by significant cost optimization—especially in raw materials and employee expenses. With a strong dividend payout and new oncology launches ahead, GSK Pharma may offer steady long-term potential despite modest revenue growth this quarter.
Disclaimer:
This article is for informational purposes only and does not constitute investment advice. Jobaaj Media, its authors, or affiliates do not endorse any specific investment action. Readers are strongly encouraged to consult a SEBI-registered financial advisor before making any investment decisions. The views of individuals or brokerages mentioned are their own and do not reflect the views of Jobaaj Media.
